Patent ID: 8822442

Claim:
A chimeric analog comprising formula (I), wherein: X is H, Cl, Br, I, F, —CN, C 1-10 alkyl, C 1-10 heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, substituted C 1-10 alkyl, substituted C 1-10 heteroalkyl, substituted C 2-10 alkenyl, or substituted C 2-10 alkynyl; R1 is H, C 1-10 alkyl, C 1-10 heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, substituted C 1-10 alkyl, substituted C 1-10 heteroalkyl, substituted C 2-10 alkenyl, substituted C 2-10 alkynyl, or —CN; R2 and R3, each is, independently, H or absent, provided that when R2 and R3 are absent a double bond is present between the carbon atoms to which they are attached; R4 is H, C 1-10 alkyl, C 1-10 heteroalkyl, C 2-10 alkenyl, C 2-10 alkynyl, substituted C 1-10 alkyl, substituted C 1-10 heteroalkyl, substituted C 2-10 alkenyl, or substituted C 2-10 alkynyl; Y is —O—, —C(O)—, —S—, —S—(CH 2 ) s —C(O)—, —S(O)—, —S(O) 2 —, —SC(O)—, —OC(O)—, —N(R5)-C(O)—, or —N(R6)-; L is —(CH 2 ) p —C(O)—, when Y is —S—, —S(O)—, —S(O) 2 —, —O— or —N(R6)-; or L is —C(O)—(CR7R8) q -C(O)—, when Y is —N(R6)-, —O—, or —S—; or L is (amino acid) t , when Y is —C(O)—, SC(O)—, —OC(O)—, —S—(CH 2 ) s —C(O)—, or —N(R5)-C(O)—; W is —CR9, R10- R5 and R6 each is, independently, H, C 1-10 alkyl, substituted C 1-10 alkyl; C 1-10 heteroalkyl, substituted C 1-10 heteroalkyl, C 2-10 alkenyl, substituted C 2-10 alkenyl, C 2-10 alkynyl, substituted C 2-10 alkynyl, aryl, alkylaryl, or substituted alkylaryl; R7, R8, R9, and R10 each is, independently, H, F, Cl, Br, I, C 1-10 alkyl, substituted C 1-10 alkyl; C 1-10 heteroalkyl, substituted C 1-10 heteroalkyl, C 2-10 alkenyl, substituted C 2-10 alkenyl, C 2-10 alkynyl, substituted C 2-10 alkynyl, aryl, alkylaryl, or substituted alkylaryl; or R7 and R8 can, optionally, join together to form a ring system; or R9 and R10 can, optionally, join together to form a ring system; i is 2-10; m is 0 or 1; n is 0-10; p is 1-10; q is 1-5; s is 1-10; t is 1-10; Z is a somatostatin analog selected from the group consisting of: DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH 2 ; DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH 2 ; DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH 2 ; cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH 2 ; DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH 2 ; and DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH 2 ; or a pharmaceutically acceptable salt thereof; and wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group, carboxylic acid group, or hydroxyl group of Z.